ABUS
BEARISH
$4.53
Live
Arbutus Biopharma Corporation · NASDAQ
Target $5.64
(+24.6%)
$2.71
52W Range
$5.1
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Mar 26, 2026
Market cap
$872.03M
P/E
N/A
ROE
-38.5%
Profit margin
-237.9%
Debt/Equity
0.05
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
ABUS exhibits severe financial distress signals with a Piotroski F-Score of 0/9, indicating extreme weakness in operational and financial health. The company reports massive negative margins, declining revenue, and unprofitable operations, with no meaningful cash flow or profitability. While the low debt-to-equity ratio and high current ratios suggest strong liquidity, they are likely inflated by non-operational cash reserves. The absence of a Graham Number and intrinsic value estimate reflects a lack of sustainable earnings, and the stock trades at a premium valuation despite deteriorating fundamentals. Analysts offer no consensus, and insider activity is neutral, reinforcing a lack of confidence.
Key Strengths
High current and quick ratios (15.73 and 15.52) indicate strong short-term liquidity
Low debt-to-equity ratio (0.05) suggests minimal leverage risk
Recent 1-year return of +34.4% shows strong price momentum despite fundamentals
Historical EPS surprise of +25.1% on average in the last 4 quarters indicates occasional outperformance
Positive year-over-year EPS growth (+57.1%) suggests some improvement in loss reduction
Key Risks
Piotroski F-Score of 0/9 signals severe financial distress and operational failure
Negative profit margins (up to -237.88%) and declining revenue (-33.20% YoY) indicate deteriorating business model
No operating cash flow or free cash flow data available, raising concerns about sustainability
No analyst target price consensus and only 3 analysts covering the stock, indicating low institutional interest
Stock trades at a massive Price/Sales of 61.92 and Price/Book of 11.38, implying extreme valuation premium without earnings support
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
14
Weak
10
30
20
10
0
AI Verdict
High Risk
Key drivers: Piotroski F-Score of 0/9, Negative profitability across all metrics, Declining revenue and unprofitable operations, No analyst consensus or target price, Extreme valuation multiples without earnings support
Confidence
90%
Value
10/100
Ref P/E, PEG, Graham Number
Positives
No standout positives identified.
Watchpoints
- No Graham Number or intrinsic value estimate due to lack of sustainable earnings
- Price/Sales of 61.92 is extremely high for a loss-making biotech
- Price/Book of 11.38 reflects premium valuation without asset backing
- Forward P/E of -27.41 indicates deep losses, not growth
Future
30/100
Ref Growth rates
Positives
- Year-over-year EPS growth of +57.1% suggests improving loss profile
- Recent quarter showed a positive surprise (+25.1% average)
Watchpoints
- Revenue growth is sharply negative (-33.20% YoY)
- No forward earnings guidance or cash flow data
- High volatility in earnings surprises (ranging from -64.5% to +40.5%)
Past
20/100
Ref Historical trends
Positives
- Historical EPS surprise average of +25.1% over last 4 quarters
- Some quarters beat estimates (e.g., +115.2% in 2025-08-06)
Watchpoints
- 25 consecutive quarters of losses with no profitability
- Most recent quarter missed estimates (-21.8%)
- Negative Q/Q EPS growth of -700.0%
Health
10/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Low debt-to-equity (0.05) and high current/quick ratios suggest strong balance sheet liquidity
Watchpoints
- Piotroski F-Score of 0/9 indicates complete failure in financial health criteria
- No Altman Z-Score available, but F-Score of 0 implies high bankruptcy risk
- Negative ROE (-38.52%) and ROA (-14.94%) reflect poor capital efficiency
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend yield or payout ratio
- Dividend Strength: 0/100
- Company is loss-making and cannot sustain dividends
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$4.53
Analyst Target
$5.64
Upside/Downside
+24.6%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ABUS and closest competitors.
Updated 2026-03-25
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ABUS
Arbutus Biopharma Corporation
Primary
|
+34.8% | +48.0% | +34.4% | +0.9% | +3.2% | +6.6% |
|
FTRE
Fortrea Holdings Inc.
Peer
|
-68.8% | -68.8% | +45.4% | -12.7% | +4.8% | -0.7% |
|
INMD
InMode Ltd.
Peer
|
-67.3% | -61.5% | -4.0% | -11.4% | +3.0% | -1.9% |
|
AMPH
Amphastar Pharmaceuticals, Inc.
Peer
|
-5.1% | -51.1% | -30.7% | -35.2% | -36.4% | -6.0% |
|
AMN
AMN Healthcare Services, Inc.
Peer
|
-72.8% | -78.8% | -26.3% | +3.5% | +28.0% | +7.7% |
ABU
Arbutus Biopharma Corporation
Primary
5Y
+34.8%
3Y
+48.0%
1Y
+34.4%
6M
+0.9%
1M
+3.2%
1W
+6.6%
FTR
Fortrea Holdings Inc.
Peer
5Y
-68.8%
3Y
-68.8%
1Y
+45.4%
6M
-12.7%
1M
+4.8%
1W
-0.7%
INM
InMode Ltd.
Peer
5Y
-67.3%
3Y
-61.5%
1Y
-4.0%
6M
-11.4%
1M
+3.0%
1W
-1.9%
AMP
Amphastar Pharmaceuticals, Inc.
Peer
5Y
-5.1%
3Y
-51.1%
1Y
-30.7%
6M
-35.2%
1M
-36.4%
1W
-6.0%
AMN
AMN Healthcare Services, Inc.
Peer
5Y
-72.8%
3Y
-78.8%
1Y
-26.3%
6M
+3.5%
1M
+28.0%
1W
+7.7%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-27.41
PEG Ratio
N/A
P/B Ratio
11.38
P/S Ratio
61.92
EV/Revenue
56.68
EV/EBITDA
-29.91
Market Cap
$872.03M
Profitability
Profit margins and return metrics
Profit Margin
-237.88%
Operating Margin
-727.31%
Gross Margin
-79.23%
ROE
-38.52%
ROA
-14.94%
Growth
Revenue and earnings growth rates
Revenue Growth
-33.2%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.05
Low debt
Current Ratio
15.73
Strong
Quick Ratio
15.52
Excellent
Cash/Share
$0.47
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q3 2025
Revenue
$0.0B
Op. Margin
-1567.7%
Net Margin
-1463.5%
Total Assets
$0.1B
Liabilities
$0.0B
Equity
$0.1B
Debt/Equity
0.26x
Operating CF
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
100%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-13
$N/A
2025-11-13
$-0.06
-21.8% surprise
2025-08-06
$0.01
+115.2% surprise
2025-05-14
$-0.18
-18.1% surprise
Healthcare Sector Comparison
Comparing ABUS against 291 companies in the Healthcare sector
(20 bullish, 99 neutral, 172 bearish)
Return on Equity (ROE)
-38.52%
This Stock
vs
-49.88%
Sector Avg
-22.8%
(Below Avg)
Profit Margin
-237.88%
This Stock
vs
-9.43%
Sector Avg
+2421.6%
(Superior)
Debt to Equity
0.05
This Stock
vs
3.74
Sector Avg
-98.5%
(Less Debt)
Revenue Growth
-33.2%
This Stock
vs
80.78%
Sector Avg
-141.1%
(Slower)
Current Ratio
15.73
This Stock
vs
3.72
Sector Avg
+322.8%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ABUS
Arbutus Biopharma Corporation
|
BEARISH | $872.03M | - | -38.5% | -237.9% | $4.53 | |
|
FTRE
Fortrea Holdings Inc.
|
BEARISH | $877.03M | - | -102.4% | -36.2% | $9.38 | Compare |
|
INMD
InMode Ltd.
|
NEUTRAL | $857.24M | 9.46 | 13.5% | 25.3% | $13.53 | Compare |
|
AMPH
Amphastar Pharmaceuticals, Inc.
|
BEARISH | $835.41M | 8.96 | 12.9% | 13.6% | $18.18 | Compare |
|
AMN
AMN Healthcare Services, Inc.
|
BEARISH | $787.1M | - | -35.9% | -10.1% | $20.49 | Compare |
ABUS
Arbutus...
BEARISH
Mkt Cap
$872M
P/E
-
ROE
-38.5%
Price
$4.53
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-02 | ANDROSKI LINDSAY J.D. | Chief Executive Officer | Stock Award | 28,000 | - |
| 2026-02-02 | NGUYEN TUAN | Chief Financial Officer | Stock Award | 73,500 | - |
ANDROSKI LINDSAY J.D.
Chief Executive Officer
2026-02-02
28,000 shares
NGUYEN TUAN
Chief Financial Officer
2026-02-02
73,500 shares
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
NONE
3 analysts
Chardan Capital
2025-11-14
Buy
Buy
Past News Coverage
Recent headlines mentioning ABUS from our newsroom.
Newest → oldest
No matching news yet.